Luis Alvarez/DigitalVision via Getty Images
- Recursion (NASDAQ:RXRX) shares rose after the company and MIT launched Boltz-2, an open-source biomolecular model.
- Boltz-2 integrates structure and binding affinity predictions and was developed using the NVIDIA-powered supercomputer, BioHive-2. (NVDA)
- The stock of the company is up 10% in morning trade.
More on Recursion Pharmaceuticals
- Recursion Pharmaceuticals: High-Risk Play Getting Riskier By The Quarter
- Recursion Pharmaceuticals, Inc. (RXRX) Q1 2025 Earnings Call Transcript
- Recursion Pharmaceuticals: Looking For Entry Around Q1 Earnings
- Recursion Pharmaceuticals outlines focused R&D pipeline with multiple catalysts through 2026
- Recursion Pharmaceuticals GAAP EPS of -$0.50 beats by $0.06, revenue of $14.75M misses by $3.33M